Genelux Corporation

Genelux Corporation is a biopharmaceutical company recognised for its breakthrough strategies in virotherapy and viral oncotherapy. The US-based company strives to create therapeutic solutions to combat cancer and other inflammatory diseases. The company employs its innovative development method in the healthcare and biotechnology sector, specialising in healthcare services, cancer treatment and genetic medicine. The company’s lead product candidate is Olvi-Vic, a proprietary, modified strain of the vaccinia virus used in the treatment of ovarian cancer and non-small-cell lung cancer. Track the share price of GNLX by adding it to your eToro watchlist.